ASTRO 2022 | Future research on SRT plus enzalutamide for PSA recurrent high-risk prostate cancer
Phuoc Tran, MD, PhD, University of Maryland, MD, discusses the future direction of research on salvage radiation therapy plus enzalutamide for high-risk PSA-recurrent prostate cancer after radical prostatectomy, including a possible further Phase III trial. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employer: University of Maryland
Consulting: Bayer, RefleXion Medical Inc & J&J
IP: Natsar Pharm
Funding sources: Astellas Pharm, Bayer Healthcare, & RefleXion Medical Inc, NIH (U01CA212007, U01CA231776 & U54CA273956), DoD (W81XWH-21-1-0296), Anonymous Donor, PCF, Distinguished Gentlemen’s Ride, Movember, Nesbitt-McMaster Foundation, Barabara’s Fund, National Capitol Cancer Research Fund
